Aurobindo Pharma Gets USFDA approval for Parkinson’s drug

Written by Meghna A Singhania Published On 2015-06-22T12:09:59+05:30 | Updated On 22 Jun 2015 12:09 PM IST

Aurobindo Pharma, the Hydrabad based Pharmaceutical company has received the approval from USFDA to produce and market market Entacapone Tablets USP, 200mg (ANDA 203437).

The approved product is bioequivalent and therapeutically equivalent to the reference listed drug product (RLD) Comtan Tablets 200mg of Orion Corporation. The tablet Entacapone functions as a catechol-O-methyl transferase (COMT) inhibitor and is used in the treatment of Parkinson's disease. This is the 39th ANDA to be approved out of Unit VII formulation facility in Hyderabad, India for manufacturing Oral Non-betalactam products

Meghna A Singhania

Meghna A Singhania is the founder and Editor-in-Chief at Medical Dialogues. An Economics graduate from Delhi University and a post graduate from London School of Economics and Political Science, her key research interest lies in health economics, and policy making in health and medical sector in the country. She is a member of the Association of Healthcare Journalists. She can be contacted at meghna@medicaldialogues.in. Contact no. 011-43720751